TG Therapeutics Inc (TGTX)

Return on total capital

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	42,809	375	102,725	49,235	20,633	-18,944	-168,691	-162,958	-192,838	-233,723	-283,888	-322,439	-344,769	-338,604	-339,198	-312,551	-273,594	-224,773	-199,912	-184,611
Long-term debt	US$ in thousands	244,429	244,158	102,537	101,326	100,118	98,908	97,700	96,503	71,135	71,135	68,947	67,249	66,788	—	—	—	7,716	15,074	22,233	29,201
Total stockholders’ equity	US$ in thousands	222,364	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353
Return on total capital		9.17%	0.09%	36.67%	18.83%	7.92%	-7.18%	-122.10%	-131.49%	-148.65%	-136.19%	-143.39%	-135.69%	-113.43%	-108.70%	-88.53%	-70.19%	-51.91%	-121.02%	-92.36%	-662.92%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $42,809K ÷ ($244,429K + $222,364K)
= 9.17%

TG Therapeutics Inc experienced a significant improvement in its return on total capital from March 2023 to December 2024. The return on total capital was negative for most of the period, indicating that the company's capital utilization was inefficient and not generating adequate returns. However, starting from September 2023, there was a notable turnaround, with the return on total capital turning positive and steadily increasing. By December 2024, the return on total capital had reached a respectable level of 9.17%, indicating that the company's capital efficiency had improved significantly. This positive trend suggests that TG Therapeutics Inc made strategic decisions that enhanced its profitability and utilization of capital during the analyzed period.